KCTD3 Knockout Jurkat Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the Jurkat human T-lymphocyte cell line, designed for disruption of the KCTD3 gene. This polyclonal pool provides a heterogeneous knockout model for studying loss-of-function effects without clonal selection. The product is supplied as a live cell population ready for expansion and experimental use in cell biology, immunology, and oncology research.
The Jurkat cell line is an immortalized human T lymphocyte originating from the peripheral blood of a 14-year-old male with acute T-cell leukemia. It serves as a widely utilized model for T-cell receptor (TCR) signaling, T-cell activation, and leukemia biology. Jurkat cells express key components of the TCR pathway and can be stimulated to induce IL-2 production, CD69 upregulation, and downstream signaling cascades, making them ideal for studying T-cell function and signaling dynamics.
KCTD3 is a putative substrate adaptor for Cullin3-RING E3 ubiquitin ligase complexes, where it interacts with CUL3 and RBX1 to facilitate the ubiquitination and subsequent proteasomal degradation of target proteins. Through this activity, KCTD3 may regulate the turnover of cell cycle regulators, apoptosis factors, or other signaling proteins. Upstream, KCTD3 expression is likely regulated by TCR signaling pathways and cellular stress responses. Its disruption is predicted to impair ubiquitin-dependent proteolysis, potentially altering the stability of downstream substrates and affecting T-cell signaling networks. The CUL3-RBX1-KCTD3 axis thus represents a node linking ubiquitin-proteasome function to immune cell regulation.
In Jurkat T cells, knockout of KCTD3 provides a system to dissect the role of Cullin3-RING ligase adaptors in lymphocyte biology. Given the Jurkat cell’s origin from a T-cell leukemia patient, this model is particularly relevant for investigating how ubiquitin-mediated proteolysis influences leukemogenic processes and T-cell survival. Disruption of KCTD3 may reveal substrates critical for proliferation, apoptosis, or TCR signaling strength, offering insights into mechanisms of malignant transformation and potential therapeutic vulnerabilities in T-cell malignancies.
Researchers can employ this polyclonal KCTD3 knockout cell pool in a variety of assays, including Western blotting and RT-qPCR to confirm target disruption, ubiquitination assays to monitor changes in protein degradation, and flow cytometry to assess cell cycle distribution and apoptosis. Functional studies of TCR signaling can be performed using IL-2 ELISA and CD69 expression analysis upon stimulation. The model is also suitable for drug screening to identify modulators of the ubiquitin-proteasome pathway. For further information or technical support, please contact Ascent Research.
